SIGA

Company Overview

A Leader in Global Health & Infectious Diseases





November 2026

Forward Looking Statements

The statements made in this presentation may include forward-looking statements regarding the treatment of smallpox and other orthopoxvirus infections, the development and attributes of SIGA Technologies, Inc. (SIGA) products, and the future operations, opportunities or financial performance of SIGA. Although we believe that the expectations contained in this presentation are reasonable, these forward-looking statements are only estimations based upon the information available to SIGA as of the date of this presentation. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. Thus, the forward-looking statements herein involve known and unknown risks and uncertainties and other important factors such that actual future operations, opportunities or financial performance may differ materially from these forward-looking statements.

Undue reliance should not be placed on forward-looking statements, which speak only as of the date hereof. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statements.

For a more detailed discussion of our risks, see the Risk Factors section in SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC and our other filings with the SEC, including our most recent Quarterly Report, all of which are available on our website, www.siga.com.





Contents

1 About SIGA

2 The Smallpox Threat

3 TPOXX®: A Differentiated Product

4 Financial Summary

SIGA At A Glance



TPOXX(1)
A Foundational Franchise & Trusted Treatment for Smallpox

30+ Countries
Where Products Have Been Sold

Strong Expertise
Infectious Disease, Health Security, and Government Contracting

Robust Balance Sheet
Disciplined Cash Management

Who We Are

SIGA is a public, commercial-stage pharmaceutical company and leader in biodefense and global health security, focused on developing and commercializing **innovative medicines** to treat and prevent **infectious diseases**, with a primary focus on **smallpox**.

Strategic Priorities

1. Continue our **partnership** with the **U.S. government**
2. Advance regulatory approvals of TPOXX in new **indications** and **formulations**
3. Cultivate strategic partnerships to expand **global access** to TPOXX
4. Leverage **capabilities** to achieve **diversification**

(1) Tecovirimat, branded as TPOXX, Tecovirimat-SIGA and TEPOXX, is approved by the U.S. FDA, Health Canada, EMA, UK MHRA, and Japan PMDA.

SIGA is a Leader in Global Health Security

Fully Integrated Infectious Disease Capabilities

- **Commercial-stage** pharmaceutical company operating within infectious disease and health security
- Experienced senior management team with **deep expertise**
- Fully integrated, **U.S.-based operational supply chain** for oral TPOXX

Leading TPOXX Product Platform

- Oral **TPOXX** is approved in the U.S., Canada, Europe, UK, and Japan
- **One of two approved antivirals** for **orthopoxvirus treatment**; strong safety and nonclinical efficacy profile
- **Track record of securing multi-year awards** with multiple governments

Foundation for Continued Attractive Growth

- **Opportunities for TPOXX expansion** (post-exposure prophylaxis "PEP", pediatric formulation)
- **Geographic expansion**
- **Inorganic growth opportunities** to expand product portfolio


Strong Historical Financial Performance

- Realized **~$680 mm of product revenue** with **robust gross margins** in 2020 – 2025
- Highly profitable company with **~$395 mm in pre-tax operating income** in 2020 – 2025
- Robust balance sheet and cash flow with **no debt**

SIGA's Path to Maximize Shareholder Value

External Trends

- Greater **awareness** of the need for **preparedness**
- Increased **vulnerability** to smallpox
- Higher **risk of smallpox** outbreaks



Government Relationships

- Long-standing collaboration with key **U.S. government agencies**
- More than a **decade** of successful contract **performance**

Core Capabilities


- Best-in-class product
- Supply and distribution
- Regulatory and development
- Operating model



The Smallpox Threat

Smallpox: Historic Milestones

Highly contagious and fatal disease in susceptible population



Smallpox Remains a Significant Threat Today

Current geopolitical environment heightens the need for vigilance

The Growing Threat

Smallpox continues to pose a serious global threat.

30%
Historic mortality rate

More than
300M
Estimated deaths in the 20th century alone from smallpox

Smallpox can spread globally before symptoms appear, leading to catastrophic impact.

The ongoing geopolitical issues and advancements in synthetic biology are increasing the likelihood of potential threats.


Vaccines alone may not be enough

Global travel increases the potential exposure facilitating the rapid spread across borders

Most of today's population is not vaccinated against smallpox, leaving millions vulnerable to its spread.

CDC Model of a 33% transmission reduction

Result: No Control



Quarantines and vaccines alone may not be enough to stop the spread of smallpox within one year.

Comprehensive Containment Measures are Critical

Vaccines and antivirals are both needed in a comprehensive biodefense preparedness plan, safeguarding vulnerable populations against smallpox threats.




TPOXX: A Differentiated Product

TPOXX: The Essentials

A highly targeted antiviral treatment against orthopoxviruses, including smallpox



As the first FDA-approved antiviral treatment for smallpox, TPOXX was among the first therapies delivered to the U.S. SNS under Project BioShield. TPOXX's was developed in partnership with, and with funding from, BARDA.



How it works

- Prevents the variola virus, which causes smallpox, from leaving infected cells
- This slows the spread of the infection allowing the immune system to clear the virus
- Has a strong safety profile and is well-tolerated in patients

Strong Preclinical and Clinical Data

- **Preclinical Data**
  - Significantly reduced both **mortality** and **viral load** in 4 pivotal studies in non-human primates and 2 pivotal studies in rabbits.
- **Clinical Data**
  - Safety demonstrated in **17 clinical trials** involving administration in **1,300+ healthy human volunteers**
  - Studies provided quantifiable pharmacokinetic (PK) data within efficacious dose ranges and resulted in no serious adverse events.

Approvals

2018	U.S. FDA	**2022**	EMA and UK MHRA
2021	Health Canada	**2024**	Japan PMDA

TPOXX is a Clinically Differentiated Medical Countermeasure

Antivirals

TPOXX
Tecovirimat SIGA, TEPOXX (ST-246/tecovirimat)

- First FDA-approved drug for the treatment of smallpox
- Targets VP37 protein of orthopoxviruses, preventing envelopment and release of virions
- **Activity against all orthopoxviruses** tested in vitro and in multiple animal models
- **Well-tolerated** in clinical trials

TEMBEXA® (CMX001/brincidofovir)

- FDA-approved drug for the treatment of smallpox
- Targets E9L DNA polymerase of orthopoxviruses and inhibits DNA synthesis
- Exhibits antiviral activity against orthopoxviruses tested in vitro and two animal models, as well as against other DNA viruses
- **Black box warning due to increased mortality** with prolonged use in another disease
- Liver function abnormalities and gastrointestinal adverse observed

Vaccines

ACAM2000® (plus other replicating vaccinia vaccine)

- Live vaccinia virus smallpox vaccine
- **Serious adverse reactions,** including death, possible, especially in patients who are immunocompromised and those with eczema or atopic dermatitis
- Up to 25% of the population would have limitations receiving the vaccine
- Most effective if given <4 days post-exposure

IMVANEX/IMVAMUNE/ JYNNEOS® (MVA-BN®)

- Modified vaccinia virus Ankara vaccine approved for prevention of smallpox and monkeypox disease in adults 18 years of age and older
- Does not replicate in mammalian cells
- Well-tolerated but requires **two doses administered 28 days apart** for full efficacy

TPOXX Demonstrates Strong Safety in Humans and Strong Efficacy in Non-Human Primates

Note: TPOXX/Tecovirimat SIGA/TEPOXX approved by the U.S., Canada, EU, UK, and Japan; TEMBEXA approved by the U.S. and Canada; ACAM2000 approved by the U.S., Australia, and Singapore; and MVA-BN approved by the U.S., Canada, and EU.


Demonstrated Track-Record of >$1B Successful Long-Standing Government Contracts for TPOXX

	2011 TPOXX CONTRACT	2018 TPOXX CONTRACT
Procurement Duration	2011 - 2018	2018 - 2026
Key Agency Involved	U.S. Biomedical Advanced Research and Development Authority (BARDA)	U.S. Biomedical Advanced Research and Development Authority (BARDA)
Contract Value	▪ $461 mm total procurement contract value ▪ $461 mm fully delivered	▪ $546 mm total procurement contract value ▪ $546 mm fully delivered

Targeting New Contract with the Administration for Strategic Preparedness & Response (ASPR) for the U.S. Strategic National Stockpile

TPOXX as a PEP Aims to Expand Health Benefits When Exposed to Smallpox

Totality of data suggests administration is optimal as early as possible or as post-exposure prophylaxis



- The current TPOXX indication leaves a **health security gap** between the time when vaccines cease to be effective and the onset of symptoms, triggering therapeutic treatment
- An **expanded label to include PEP would address this gap**
- Nonclinical studies have shown that **early administration of TPOXX after exposure leads to improved outcomes**


Note: TPOXX is not approved as a post-exposure prophylaxis in any jurisdiction.




Financial Summary

Strong Financial Performance Over Time


Product Revenues ($mm)




Pre-tax Operating Income ($mm)



Capital Management[1] ($mm)



Averages for 2020 – 2025 ($mm)



Balance Sheet at September 30, 2026

- Cash balance of $116 million
- No debt

(1) Includes dividends and share repurchases.

Our Financial Journey: 2020 to 2025

1 U.S. Government Orders

- $546 mm of TPOXX ordered for the SNS
- $30 mm of oral TPOXX ordered by the Department of Defense

2 International Orders

- $135 mm of oral TPOXX ordered by 30+ international customers

3 Cumulative Results

- $680 mm of total product revenues
- $395 mm of cumulative pre-tax operating income

($ in millions)	2020	2021	2022	2023	2024	2025
Product Revenues						
Oral TPOXX (U.S. Government)	$113	$113	$7	$110	$84	$53
Oral TPOXX (International)	$2	$13	$71	$21	$23	$6
IV TPOXX	–	–	$7	–	$26	$26
Other	–	–	–	–	–	$3
Total	**$115**	**$127**	**$87**	**$131**	**$133**	**$88**
Pre-Tax Operating Income	**$85**	**$89**	**$43**	**$84**	**$70**	**$24**
Net Income	**$56**	**$69**	**$34**	**$68**	**$59**	**$23**

Key Takeaways

Leveraging Infectious Disease Foundation	Building on Successful TPOXX Franchise	Driving Organic Growth Initiatives	Expanding Platform with Inorganic Growth	Maintaining a Robust Balance Sheet
Leading **health security** and **infectious disease** pharmaceutical company with a **fully integrated** business with commercial, R&D, supply chain, and government relations capabilities	Proven **track record** of success having received > $1 bn in **government contracts** and delivered to governments around the globe	Multiple organic **growth opportunities** across both label expansion and geographic expansion	Attractive opportunities to expand the **product portfolio** with synergies	Strong **balance sheet,** with substantial cash and no debt